|
|
Vaccine Detail
|
HER2 ICD peptide vaccine |
| Vaccine Information |
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: HER-2/neu intracellular domain protein (NCT00343109)
- Immunization Route: Intradermal injection (i.d.)
- Description: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Patients with HER2 positive locally advanced breast cancer can be vaccinated with a HER2 Intracellular Domain (ICD) peptide-based vaccine administered concurrently with trastuzumab. The vaccine may lead to an immune response (HER2 specific T cell immunity and/or the development of intramolecular epitope spreading). (NCT00343109)
|
| Host Response |
|
|
| References |
NCT00343109: Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer [https://clinicaltrials.gov/study/NCT00343109]
|
|
